

## Resubmission

**Zoledronic acid (Zometa<sup>®</sup>)**

**(No. 29/02)**

**Novartis Europharm Ltd**

### Summary of Recommendation

9 May 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

#### **ADVICE**

Zoledronic acid is recommended for restricted within NHS Scotland.

#### **RECOMMENDATION**

Use of this product should be restricted to prescribing by oncologists for **patients with breast cancer and multiple myeloma**. It provides an alternative to other bisphosphonates licensed for prevention of skeletal related events. It may offer some minor advantages in terms of administration. At a local level the decision will rest on weighing up the additional cost against other options available for improving the delivery of oncology services.

Zoledronic acid has a broader range of indications than other bisphosphonates available and has shown some efficacy in patients with prostate cancer and NSCLC and other solid tumours. The quality of the economic evidence provided is insufficient to demonstrate that the use of this product for these indications is cost effective.

The licence holder has indicated their decision to appeal.

Professor David H Lawson  
Chairman